GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) - Full Text View

Sponsor:	Pfizer
Information provided by (Responsible Party):	Pfizer
ClinicalTrials.gov Identifier:	NCT00373685

Purpose

This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.

Condition	Intervention	Phase
Osteoarthritis	Drug: Celecoxib Drug: Any commercially available NSAID with the indication for osteoarthritis	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Gastrointestinal (GI) Randomized Event And Safety Open-Label NSAID Study (GI-Reasons): A Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS) In Osteoarthritis Patients

Resource links provided by NLM:

MedlinePlus related topics: Osteoarthritis

Drug Information available for: Celecoxib

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:

Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) [ Time Frame: Baseline through week 24 or Early Termination (ET) ] [ Designated as safety issue: Yes ]
CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin.

Secondary Outcome Measures:

Percentage of Participants With Moderate to Severe Abdominal Symptoms [ Time Frame: Baseline through week 24 or ET ] [ Designated as safety issue: Yes ]
Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms"; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function.
Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs) [ Time Frame: Baseline through week 24 or ET ] [ Designated as safety issue: Yes ]
GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions
Hemoglobin (Hb) at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Change From Baseline Hb at Week 24 [ Time Frame: Baseline and Week 24 or ET ] [ Designated as safety issue: Yes ]
Hematocrit (Hct) at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
Change From Baseline Hct at Week 24 [ Time Frame: Week 24 or ET ] [ Designated as safety issue: Yes ]
Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline [ Time Frame: Baseline, Weeks 8, 16, 24 or ET ] [ Designated as safety issue: Yes ]
Clinically significant decrease in Hct (greater than or equal to 10 percent [≥10%]) and/or decrease in Hb (≥ 2 g/dL).
Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall [ Time Frame: Baseline, Weeks 8, 16, 24 or ET ] [ Designated as safety issue: No ]
Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5).
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief [ Time Frame: Baseline, Weeks 8, 16, 24 or ET ] [ Designated as safety issue: No ]
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief [ Time Frame: Baseline, Weeks 8, 16, 24 or ET ] [ Designated as safety issue: No ]
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief [ Time Frame: Baseline, Weeks 8, 16, 24 or ET ] [ Designated as safety issue: No ]
Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

Enrollment:	8067
Study Start Date:	October 2006
Study Completion Date:	November 2010
Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Celecoxib dosing as per USPI label	Drug: Celecoxib open-label
Active Comparator: NSAIDs	Drug: Any commercially available NSAID with the indication for osteoarthritis dosing as per USPI label related to the chosen commercially marketed NSAID

Eligibility

Ages Eligible for Study:	55 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female patients of at least 55 years of age with a clinical diagnosis of OA who are expected to require daily prescription anti-inflammatory analgesic therapy for arthritis symptom management and for whom either celecoxib or a nsNSAID is an appropriate treatment option.

Exclusion Criteria:

GI ulcer hemorrhage or active GD ulceration less than 90 days prior to screening visit.
Patients with a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, transient ischemic attack, previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00373685

Show 777 Study Locations

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Additional Information:

To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Pfizer
ClinicalTrials.gov Identifier:	NCT00373685 History of Changes
Other Study ID Numbers:	A3191331
Study First Received:	September 7, 2006
Results First Received:	October 26, 2011
Last Updated:	February 2, 2012
Health Authority:	United States: Food and Drug Administration

Keywords provided by Pfizer:

GI events in patients with moderate GI risk treated with NSAIDS

Additional relevant MeSH terms:

Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Celecoxib
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Therapeutic Uses
Pharmacologic Actions
Analgesics, Non-Narcotic

Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 09, 2012